Joseph Stringer: Hi, good morning. Thanks for taking our questions. Just wanted to get your updated thoughts on the European BBS launch and how it would could compare to the U.S. launch to date? It looks like European BBS patients, more of them are identified and the community is more organized, but you have the dynamics of the staggered reimbursement process. So, how do you anticipate European launch playing out and perhaps maybe using Germany as an example? You have the 250 patients ID-ed, could we expect a similar rate of TRF add relative to what has been seen in the U.S. today?
David Meeker: Yes. I think, Joe, I’ll turn it over to Yann, one second, just to highlight, you are correct that the European is better experience or situation, is better organized and more identified, but you highlighted may have a different pace. So, Yann?
Yann Mazabraud: Yes. Maybe I will start with the German launch versus the U.S. and I will end on the overall European situation. So, first Germany and the U.S. So, you’re right. There are between the two countries and the most important one is the decentralized healthcare and decentralization of the care. And as I’ve said in my presentation, we already know more than almost 20 large hospitals where they are diagnosed BBS patients where patients will be treated. There is a main difference, which is really the pace of starting the treatment, the German physicians are well-known to be more conservative than the average. And we know that it will be patient by patient decisions like for any other rare disease. So that’s Germany versus the U.S. And then back to the overall question of Europe.
It’s a bit early to speak in terms of trajectories. For insulin Europe, first because Germany is our first important launch. And second, most of the important European country will launch at the end of the year, Italy, Netherlands, Spain, etcetera. And at the end of 2024 for the UK. So, still a bit early.
David Meeker: Thanks, Yann. Joe is that covered.
Joseph Stringer: Great. Thank you for taking our questions.
Operator: Thank you. Alright. Our next question comes from the line of … Alright. Our next question comes from the line of Jeff Hung from Morgan Stanley. Your line is now open.
Jeff Hung: Thanks for taking my questions. For the low number of patients discontinuing due to hyperpigmentation, do you have a sense from those patients how their hyperphasia was? Do they happen to have lower hyperphasia than other BBS patients so the hyperpigmentation overrides that? And then I have a follow-up.
David Meeker: Jeff, just to highlight again, the number of patients because of hyperpigmentation is extremely low, so one that’s been reassuring, but on those specific cases .
Jennifer Chien: I don’t think it’s necessarily correlated with the hyper phased in terms of the reasons for the discounts. I think that it’s patient-by-patient just in terms of how problematic the hyperpigmentation is for that particular patient. And once again, I think as the patient’s discount and they feel the resurgence of the hyperphagia itself, they can also be at a decision point once again just in terms of really deciding whether to discontinue or to reinitiate therapy. So, our teams are there regardless to support them as they go on their path forward.
Jeff Hung: Okay. Thanks. And then I know it’s a bit early, but with the recommended weight loss monitoring after one-year of treatment, do you have a rough sense for the proportion of patients that started on commercial drug fairly early in the launch that have already seen at least 5% loss in body weight or BMI? Just trying to get a gauge the potential impact of discontinuations based on this recommendation? Thanks.
